teed up • Short time & limited capital to profit/liquidity • Managing Director's hands-on involvement • Competitive fees - 2%/20% DAC..., CAPITAL Li_c EFTA_R1_01138808 EFTA02295534 The Case for Investment ■ Biotechnology Big markets - big valuations Big need - big pharma Modern medicine • C